- Maribo Medico has been ResMed's exclusive distribution partner
in Denmark for more than 15
years.
- Together ResMed and Maribo will help improve the lives for
more of Denmark's estimated
750,000 people with obstructive sleep apnea (OSA) and 400,000
suffering from chronic obstructive pulmonary disease (COPD).
SAN DIEGO, Nov. 16, 2015 /PRNewswire/ -- ResMed
(NYSE:RMD) today announced it has acquired Maribo Medico, a
privately-held company specializing in the education, diagnosis,
treatment and management of sleep-disordered breathing and
respiratory diseases. Maribo Medico is Denmark's market leader in providing
sleep-disordered breathing medical devices and accessories.
"Maribo Medico's strong team and talented leadership, their
market reputation, and their commitment to research and
education for sleep and respiratory medicine have helped tens of
thousands of people in Denmark who
suffer from sleep-disordered breathing and chronic obstructive
pulmonary disease," said Anne Reiser, president of ResMed
EMEA-APAC. "Maribo and ResMed together will accelerate growth while
improving patient quality-of-life and reducing total healthcare
system costs in Denmark. This
combination is part of our global goal of improving 20 million
lives by 2020."
Maribo Medico employees, including Chief Executive Officer Mette
Toxværd Larsen, will continue on in their current roles.
"We are very happy to join with ResMed to help even more people
who suffer from sleep-disordered breathing or chronic respiratory
diseases," said Toxværd Larsen. "We've had a strong and fruitful
partnership with ResMed for more than 15 years, and now we will
leverage their global strength to improve many more lives in
Denmark, building our position in
respiratory care and digital, tele-monitoring solutions."
Financial terms of the transaction were not disclosed.
About Maribo Medico
Founded in 1996/1997 and based in Sjaelland, Denmark, Maribo Medico is Denmark's leading value-added distributor
specializing in providing quality products, compliance and
education related to the diagnosis, treatment and management of
sleep disordered breathing and respiratory diseases.
About ResMed
The global team at ResMed (NYSE:RMD) is united in the commitment
to change millions of lives with every breath. With more than
4,000 employees and a presence in over 100 countries, the company
has been pioneering new and innovative devices and treatments for
sleep-disordered breathing, chronic obstructive pulmonary disease,
and other chronic diseases for more than 25 years. ResMed's
world-leading products and innovative solutions improve the quality
of life for millions of patients worldwide, reduce the impact of
chronic disease, and save healthcare costs. For more information
about ResMed and its businesses, visit www.resmed.com or follow
@resmed on Twitter.
ResMed Contacts:
|
|
For News Media
|
For Investors
|
Alison Graves
|
Agnes Lee
|
Global Corporate Communications
|
Senior Director, Investor Relations
|
O: +1. 858-836-6789
|
O: +1. 858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|